CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
IPFA welcomes Marion Lanteri as Executive Board member, CTS as new member organization
Creative Testing Solutions, the largest nonprofit blood testing organization in the U.S., today anno...
On June 13, 2019, the new CTS Laboratory Information System was successfully implemented in Cha...
Josh Moon has been appointed Chief Operating Officer (COO) at Creative Testing Solutions (CTS), effe...
That’s just one of the reasons that National Blood Donor Month, which has taken place each Jan...
TEMPE, Ariz. (Sept. 8, 2022) — Marion Lanteri, Ph.D., began this week as Creative Testing Solu...